This trial is testing a new drug for people with myelofibrosis who can't take other treatments.
- Primary Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
- Post Polycythemia Vera Myelofibrosis
1 Primary · 4 Secondary · Reporting Duration: Up to 24 months
Side Effects for
1 Treatment Group
Selinexor, all patients
1 of 1
56 Total Participants · 1 Treatment Group
Primary Treatment: Selinexor · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is this experiment the pioneering effort of its type?
"Since 2014, Selinexor has garnered considerable attention from the medical community. Karyopharm Therapeutics Inc. sponsored its first clinical trial in that year with 16 participants and eventually received Phase 1 drug approval following this initial study. Presently there are 48 ongoing trials for Selinexor across 259 cities and 28 nations worldwide." - Anonymous Online Contributor
Is Selinexor deemed a secure option for individuals?
"There is preliminary clinical data verifying the safety of Selinexor, so it received a rating of 2." - Anonymous Online Contributor
Are enrollment opportunities available for this trial at present?
"Affirmative. Clinicaltrials.gov data reveals that this research is presently recruiting participants, with the first post made on May 10th 2019 and last update on May 3rd 2022. 56 people are being admitted from a single clinical site." - Anonymous Online Contributor
What prior experimental studies have been conducted using Selinexor?
"Currently, Selinexor has 48 ongoing clinical trials with 4 in the late-stage Phase 3. While Bethesda, Maryland is one of several research sites for this medication, it can be found at 922 locations worldwide." - Anonymous Online Contributor
What is the current capacity for enrollees in this research protocol?
"Affirmative. The clinical trial listing on clinicaltrials.gov displays that recruitment for this study is currently underway; it was initially posted on May 10th 2019 and most recently modified on May 3rd 2022. 56 participants need to be recruited from a single location." - Anonymous Online Contributor